have shown that intracoronary administration of autologous CD34+ cell therapy effectively alleviates angina and endothelial dysfunction in non-obstructive coronary artery disease, highlighting the potential of this therapeutic approach to address these complex cardiovascular conditions. Here, CD34 is linked to endothelial dysfunction.